MedTrace Logo

Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy

NCT01609153 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 328

Last updated 2019-04-16

No results posted yet for this study

Summary

A study to examine whether an antipsychotic combination treatment of olanzapine and amisulpride is more effective than olanzapine and amisulpride alone.

Conditions

Interventions

DRUG

Olanzapine

Coated tablet 5-20 mg milligram(s) per day for 16 weeks

DRUG

Amisulpride

200-800 mg milligram(s)per day for 16 weeks

DRUG

Olanzapine and Amisulpride

Zyprexa: Coated tablet 5-20 mg milligram(s) per day for 16 weeks Amisulpride: Coated tablet 200-800 mg milligram(s)per day for 16 weeks

Sponsors & Collaborators

  • Heinrich-Heine University, Duesseldorf

    lead OTHER

Principal Investigators

  • Christian Schmidt-Kraepelin, Dr. · Heinrich-Heine University, Duesseldorf

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01609153 on ClinicalTrials.gov